The company is moving to the clinic which is a change of direction from what we currently do IMO, licensing midkine. Maria is a managing director and CEO, what I am saying is surely it 'could' be in the companys interests and that of a large Shareholding director and CEO to see the value in a CEO who is more experienced in clinical trials. Have a look at Maria's LinkedIn profile, she is a deal maker, as a director she can still have this capacity.
Would she take a paycut to bring someone more experienced in the clinic to the table? Well, I guess that is the question.
The company is moving to the clinic which is a change of...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable